Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Alnylam and Arrowhead Form Collaboration and Licensing Agreement
– Arrowhead Receives License from Alnylam to Develop RNAi Therapeutic Toward Hepatitis B Virus (HBV) – – Alnylam Gains Access to Arrowhead's Dynamic Polyconjugate (DPC) Delivery Technology for "Alnylam 5x15" Target –
View HTML
Toggle Summary Amgen and Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations View HTML
Toggle Summary Arrowhead Acquires Novartis' RNAi Research and Development Portfolio
- Conference Call Today at 8:30 a.m. EST PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced the acquisition of Novartis' entire RNAi research and development portfolio and associated
View HTML
Toggle Summary Arrowhead Added to NASDAQ Biotechnology Index®
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Research Corporation ( NASDAQ : ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it has been selected for addition to the NASDAQ Biotechnology Index ( NASDAQ : NBI) as part of the annual re-ranking which
View HTML
Toggle Summary Arrowhead and Shire Enter into Collaboration and License Agreement to Develop Peptide-Targeted Therapeutics
Arrowhead and Shire Enter into Collaboration and License Agreement to Develop Peptide-Targeted Therapeutics PASADENA, Calif. — December 18, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it has signed a research collaboration and license
View HTML
Toggle Summary Arrowhead and Spring Bank Announce Clinical Collaboration for ARC-520 and SB 9200 in Chronic Hepatitis B
PASADENA, Calif. & HOPKINTON, Mass. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. ( NASDAQ : ARWR) and Spring Bank Pharmaceuticals, Inc. ( NASDAQ : SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory
View HTML
Toggle Summary Arrowhead Announces Dosing of First Patient with Anti-Obesity Treatment Adipotide® in a Phase 1 Clinical Trial
Arrowhead Announces Dosing of First Patient with Anti-Obesity Treatment Adipotide® in a Phase 1 Clinical Trial PASADENA, Calif. — July 11, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that the first patient has been dosed in a Phase 1
View HTML
Toggle Summary Arrowhead Announces FDA Clearance to Initiate Adipotide™ Phase I Clinical Trial
Arrowhead Announces FDA Clearance to Initiate Adipotide™ Phase I Clinical Trial PASADENA, Calif. — January 4, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, today announced that the Investigational New Drug Application
View HTML
Toggle Summary Arrowhead Announces Inducement Grants Under NASDAQ Rule 5635(c)(4)
Arrowhead Announces Inducement Grants Under NASDAQ Rule 5635(c)(4) PASADENA, Calif. — October 25, 2013 — Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced it awarded "inducement" options to two new employees under Rule
View HTML
Toggle Summary Arrowhead Announces New Clinical Candidate ARC-AAT for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
RNAi Therapeutic ARC-AAT Induces Dose Dependent Reductions in Mutant AAT Protein of Greater than 95 Percent in Preclinical Studies Long Duration of Effect with AAT Remaining Reduced by More than 80% at 6 Weeks after a Single Dose Company Receives Funding from The Alpha-1 Project to Support ARC-AAT
View HTML